Against Our Instincts: Decriminalization of Buprenorphine

4Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

The rate of overdose deaths has increased dramatically over the past 2 decades. Recently, efforts have been made to expand access to medications for opioid use disorder, such as buprenorphine, by removing Xwaiver training requirements. However, relieving such barriers has also raised concern about increasing diversion rates for buprenorphine use, defined as the use of buprenorphine for some purpose or by someone other than it was originally intended. Historically, diversion has been addressed through the criminalization of buprenorphine possession without a prescription. We argue that while buprenorphine diversion is not to be condoned, the benefits of such actions greatly outweigh the harms. Thus, criminalization of diverted buprenorphine represents a dangerous and wasteful response that threatens the progress made through expanded access to this lifesaving medication.

Cite

CITATION STYLE

APA

Messinger, J. C., Chukka, A., & Boyd, J. W. (2022). Against Our Instincts: Decriminalization of Buprenorphine. Journal of the American Board of Family Medicine, 35(2), 394–397. https://doi.org/10.3122/jabfm.2022.02.210308

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free